We also determined the expression of TCF3 in the tumor tissues by immunoblotting analysis and immunohistochemistry, the results of which confirmed that TCF3 does promote the progression of ESCC in vivo (Figure 5E,F). This evidence concerns the gene TCF3 and neoplasm.